摘要
肺癌是全球发病率及死亡率最高的恶性肿瘤,虽然含铂双药化疗一定程度上提高了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效,但预后仍欠佳。为了进一步改善患者的生存,进行有效的维持治疗至关重要。本文就晚期NSCLC维持治疗的研究现状进行综述,探讨维持治疗的临床意义及如何选择个体化治疗方案。
Lung cancer is a malignant tumor associated with the highest morbidity and mortality worldwide.Although platinum-based doublet chemotherapy has moderately improved the efficacy in advanced non-small cell lung cancer(NSCLC),prognosis of patients with NSCLC remains poor.To further improve the survival of patients with NSCLC,effective maintenance therapy is essential.This study reviews the current status of advanced NSCLC maintenance therapy and discusses the clinical significance of maintenance therapy and the selection process of an individualized treatment plan.
作者
周倩(综述)
谭榜宪(审校)
Qian Zhou;Bangxian Tan(Department of Oncology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China;Department of Oncology,Chongqing University Three Gorges Hospital,Chongqing 404000,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2021年第12期631-635,共5页
Chinese Journal of Clinical Oncology
关键词
非小细胞肺癌
维持治疗
靶向治疗
免疫治疗
联合治疗
non-small cell lung cancer(NSCLC)
maintenance therapy
targeted therapy
immunotherapy
combination therapy
